Crescent Biopharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
38.0%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$2.49next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Initiation of CR-001 and ADC Combination Trial | 31 Dec 2026 |
| CR-001 ASCEND Trial Proof-of-Concept Data Readout | 31 Mar 2027 |
| CR-003 Chinese Phase 1/2 Trial Proof-of-Concept Data Readout | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly189.2MTarget: Sufficient to fund operations into 2028
ASCEND Phase 1/2 Trial Enrollment QuarterlyTarget: Up to 290 patients
Watch Items
- CR-001 ASCEND Trial Proof-of-Concept DataTrigger: Initial safety, PK/PD, and preliminary antitumor activity from dose escalation and backfill cohortsAction: Evaluate clinical efficacy and safety profile to validate cooperative PD-1 x VEGF bispecific mechanism
- CR-002 IND Submission and Phase 1/2 Trial InitiationTrigger: IND submission in mid-2026 and trial initiation in H2 2026Action: Monitor regulatory clearance and first-patient-dosed milestone for the PD-L1-targeted ADC
- CR-003 Phase 1/2 Trial Progress in ChinaTrigger: Proof-of-concept data from Kelun-Biotech's Chinese trial in Q1 2027Action: Review clinical data to support global development and planned combination trials with CR-001
Research as of 20 Jun 2026